Temozolomide Induced Hypermutation in Glioma: Evolutionary Mechanisms and Therapeutic Opportunities
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Temozolomide Induced Hypermutation in Glioma: Evolutionary Mechanisms and Therapeutic Opportunities
Authors
Keywords
-
Journal
Frontiers in Oncology
Volume 9, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2019-02-04
DOI
10.3389/fonc.2019.00041
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Tumor Evolution of Glioma-Intrinsic Gene Expression Subtypes Associates with Immunological Changes in the Microenvironment
- (2018) Qianghu Wang et al. CANCER CELL
- Radiotherapy Upregulates Programmed Death Ligand-1 through the Pathways Downstream of Epidermal Growth Factor Receptor in Glioma
- (2018) Xing Song et al. EBioMedicine
- Combining radiation therapy and cancer immune therapies: From preclinical findings to clinical applications
- (2018) S. Bockel et al. Cancer Radiotherapie
- Abscopal effect of radiotherapy combined with immune checkpoint inhibitors
- (2018) Yang Liu et al. Journal of Hematology & Oncology
- Mutational Landscape of Secondary Glioblastoma Guides MET-Targeted Trial in Brain Tumor
- (2018) Huimin Hu et al. CELL
- Genetic, epigenetic and immunologic profiling of MMR-deficient relapsed glioblastoma
- (2018) Stefano Indraccolo et al. CLINICAL CANCER RESEARCH
- Divergent evolution of temozolomide resistance in glioblastoma stem cells is reflected in extracellular vesicles and coupled with radiosensitization
- (2017) Delphine Garnier et al. NEURO-ONCOLOGY
- Mutational burden, immune checkpoint expression, and mismatch repair in glioma: implications for immune checkpoint immunotherapy
- (2017) Tiffany R. Hodges et al. NEURO-ONCOLOGY
- Tumor Mutational Burden and Response Rate to PD-1 Inhibition
- (2017) Mark Yarchoan et al. NEW ENGLAND JOURNAL OF MEDICINE
- M2 macrophages are more resistant than M1 macrophages following radiation therapy in the context of glioblastoma
- (2017) Marine M. Leblond et al. Oncotarget
- Chromatin marks shape mutation landscape at early stage of cancer progression
- (2017) Kyungsik Ha et al. npj Genomic Medicine
- The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary
- (2016) David N. Louis et al. ACTA NEUROPATHOLOGICA
- Immune Checkpoint Inhibition for Hypermutant Glioblastoma Multiforme Resulting From Germline Biallelic Mismatch Repair Deficiency
- (2016) Eric Bouffet et al. JOURNAL OF CLINICAL ONCOLOGY
- Dedifferentiation of Glioma Cells to Glioma Stem-like Cells By Therapeutic Stress-induced HIF Signaling in the Recurrent GBM Model
- (2016) Gina Lee et al. MOLECULAR CANCER THERAPEUTICS
- Clonal evolution of glioblastoma under therapy
- (2016) Jiguang Wang et al. NATURE GENETICS
- Immunogenomics of Hypermutated Glioblastoma: A Patient with Germline POLE Deficiency Treated with Checkpoint Blockade Immunotherapy
- (2016) T. M. Johanns et al. Cancer Discovery
- Association of the Extent of Resection With Survival in Glioblastoma
- (2016) Timothy J. Brown et al. JAMA Oncology
- Evolution of DNA repair defects during malignant progression of low-grade gliomas after temozolomide treatment
- (2015) Hinke F. van Thuijl et al. ACTA NEUROPATHOLOGICA
- Minor Changes in Expression of the Mismatch Repair Protein MSH2 Exert a Major Impact on Glioblastoma Response to Temozolomide
- (2015) J. L. McFaline-Figueroa et al. CANCER RESEARCH
- Structural and functional features of central nervous system lymphatic vessels
- (2015) Antoine Louveau et al. NATURE
- Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma
- (2014) A. P. Patel et al. SCIENCE
- The Changes in MGMT Promoter Methylation Status in Initial and Recurrent Glioblastomas
- (2014) Chul-Kee Park et al. Translational Oncology
- The Somatic Genomic Landscape of Glioblastoma
- (2013) Cameron W. Brennan et al. CELL
- CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2006-2010
- (2013) Q. T. Ostrom et al. NEURO-ONCOLOGY
- Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics
- (2013) A. Sottoriva et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Mutational Analysis Reveals the Origin and Therapy-Driven Evolution of Recurrent Glioma
- (2013) B. E. Johnson et al. SCIENCE
- Inflammatory cell trafficking across the blood-brain barrier: chemokine regulation and in vitro models
- (2012) Yukio Takeshita et al. IMMUNOLOGICAL REVIEWS
- A restricted cell population propagates glioblastoma growth after chemotherapy
- (2012) Jian Chen et al. NATURE
- Increased Microglia/Macrophage Gene Expression in a Subset of Adult and Pediatric Astrocytomas
- (2012) Jane R. Engler et al. PLoS One
- Correlation of MGMT promoter methylation status with gene and protein expression levels in glioblastoma
- (2011) Miyuki Uno et al. Clinics
- Promoter methylation and expression of MGMT and the DNA mismatch repair genes MLH1, MSH2, MSH6 and PMS2 in paired primary and recurrent glioblastomas
- (2011) Jörg Felsberg et al. INTERNATIONAL JOURNAL OF CANCER
- Improved survival time trends for glioblastoma using the SEER 17 population-based registries
- (2011) Matthew Koshy et al. JOURNAL OF NEURO-ONCOLOGY
- Identification of a CpG Island Methylator Phenotype that Defines a Distinct Subgroup of Glioma
- (2010) Houtan Noushmehr et al. CANCER CELL
- Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1
- (2010) Roel G.W. Verhaak et al. CANCER CELL
- Mismatch-repair protein MSH6 is associated with Ku70 and regulates DNA double-strand break repair
- (2010) Ankita Shahi et al. NUCLEIC ACIDS RESEARCH
- IDH1andIDH2Mutations in Gliomas
- (2009) Hai Yan et al. NEW ENGLAND JOURNAL OF MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started